
Last update at 2026-06-03T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 525.30M | 579.30M | 437.40M | 580.50M | 774.30M |
| Minority interest | 0.60M | 7.10M | 34.80M | 11.80M | 2.90M |
| Net income | 397.35M | 432.20M | 357.60M | 452.40M | 601.10M |
| Selling general administrative | 1111.20M | 313.80M | 295.00M | 253.20M | 242.60M |
| Selling and marketing expenses | - | 783.80M | 725.50M | 701.50M | 575.70M |
| Gross profit | 2141.20M | 2215.30M | 2057.30M | 2008.60M | 1963.70M |
| Reconciled depreciation | 438.40M | 325.20M | 388.50M | 277.00M | 231.00M |
| Ebit | 560.99M | 595.30M | 569.00M | 665.60M | 802.90M |
| Ebitda | 999.23M | 897.50M | 857.80M | 942.60M | 1033.90M |
| Depreciation and amortization | 438.24M | 302.20M | 288.80M | 277.00M | 231.00M |
| Non operating income net other | - | - | - | - | - |
| Operating income | 560.99M | 588.80M | 439.00M | 587.20M | 784.30M |
| Other operating expenses | 3507.29M | 3391.10M | 3235.70M | 2925.30M | 2575.20M |
| Interest expense | 15.80M | 16.56M | 4.40M | 4.10M | 9.10M |
| Tax provision | 128.80M | 154.30M | 114.50M | 140.10M | 175.60M |
| Interest income | 13.20M | 0.50M | 1.40M | 1.20M | 1.70M |
| Net interest income | 4.30M | -9.40000M | -1.70000M | -5.20000M | -9.80000M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 128.75M | 154.30M | 114.50M | 140.10M | 175.60M |
| Total revenue | 4068.28M | 3979.90M | 3674.70M | 3589.00M | 3376.20M |
| Total operating expenses | 1580.21M | 1626.50M | 1618.30M | 1344.90M | 1162.70M |
| Cost of revenue | 1927.08M | 1764.60M | 1617.40M | 1580.40M | 1412.50M |
| Total other income expense net | -35.68663M | -9.50000M | -1.60000M | -6.70000M | -10.00000M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 396.80M | 425.10M | 322.90M | 440.40M | 598.00M |
| Net income applicable to common shares | - | - | - | 452.40M | 601.10M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 5572.61M | 5770.00M | 5259.20M | 5186.60M | 4616.80M |
| Intangible assets | 401.35M | 492.00M | 528.60M | 625.00M | 411.50M |
| Earning assets | - | - | - | - | - |
| Other current assets | - | 156.40M | 215.70M | 38.80M | 43.70M |
| Total liab | 1468.15M | 1559.00M | 1507.00M | 1543.70M | 1442.20M |
| Total stockholder equity | 4100.56M | 4204.90M | 3752.20M | 3604.20M | 3123.20M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 670.95M | 686.10M | 606.00M | 122.50M | 95.90M |
| Common stock | 12.00M | 12.00M | 12.00M | 12.00M | 12.00M |
| Capital stock | 12.00M | 12.00M | 12.00M | 12.00M | 12.00M |
| Retained earnings | 397.50M | 432.20M | 357.60M | 452.40M | 601.10M |
| Other liab | - | - | - | 94.20M | 123.70M |
| Good will | 727.53M | 730.40M | 698.80M | 812.50M | 669.50M |
| Other assets | - | -0.10000M | 0.10M | 0.10M | 0.10M |
| Cash | 569.59M | 449.80M | 352.40M | 552.60M | 803.50M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 1064.30M | 1134.90M | 1087.30M | 1131.10M | 955.90M |
| Current deferred revenue | - | - | 52.80M | 552.20M | 520.80M |
| Net debt | -108.35940M | 40.90M | 166.40M | -47.20000M | -341.00000M |
| Short term debt | 131.35M | 141.00M | 163.40M | 187.00M | 99.70M |
| Short long term debt | 99.30M | 111.60M | 136.10M | 160.80M | 99.70M |
| Short long term debt total | 461.23M | 490.70M | 518.80M | 505.40M | 462.50M |
| Other stockholder equity | 4088.57M | 3760.70M | 3401.10M | 3139.80M | 2510.10M |
| Property plant equipment | - | - | - | 1369.90M | 1224.80M |
| Total current assets | 2539.45M | 2501.10M | 2205.20M | 2216.60M | 2207.10M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | - | 2166.70M | 2042.10M |
| Short term investments | - | - | 14.20M | -19.80000M | -27.50000M |
| Net receivables | 1010.52M | 857.60M | 728.60M | 740.10M | 701.40M |
| Long term debt | 211.30M | 207.10M | 234.10M | 224.80M | 362.80M |
| Inventory | 959.34M | 1037.30M | 908.50M | 737.20M | 634.60M |
| Accounts payable | 262.00M | 272.40M | 265.10M | 269.40M | 239.50M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | -18.50000M | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 10.30M | 24.80M | 114.60M | 12.80M | 12.50M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 3033.16M | 3268.90M | 3054.00M | 2969.90M | 2409.60M |
| Capital lease obligations | 150.80M | 172.00M | 148.60M | 119.90M | 122.40M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -1.00000M | -359.80000M | -488.80000M | -528.10000M | -0.40000M |
| Change to liabilities | - | - | - | 9.90M | 24.20M |
| Total cashflows from investing activities | -461.52708M | -359.80000M | -488.80000M | -528.10000M | -307.30000M |
| Net borrowings | -29.60000M | -74.80000M | -34.80000M | 14.30M | -50.10000M |
| Total cash from financing activities | -155.34180M | -212.60000M | -122.30000M | -244.20000M | -127.00000M |
| Change to operating activities | - | - | - | 71.90M | -21.80000M |
| Net income | 397.35M | 425.10M | 322.80M | 440.50M | 598.20M |
| Change in cash | 173.28M | 108.70M | -195.30000M | -258.60000M | 416.00M |
| Begin period cash flow | 396.31M | 333.40M | 528.70M | 787.30M | 371.30M |
| End period cash flow | 569.59M | 442.10M | 333.40M | 528.70M | 787.30M |
| Total cash from operating activities | 788.00M | 667.30M | 445.40M | 475.10M | 811.10M |
| Issuance of capital stock | - | - | - | 0.00000M | 0.00000M |
| Depreciation | 438.24M | 325.20M | 258.90M | 277.00M | 231.00M |
| Other cashflows from investing activities | -0.09996M | 0.60M | -0.00000M | - | - |
| Dividends paid | 106.06M | 100.20M | 100.20M | -101.20000M | -73.10000M |
| Change to inventory | -10.09622M | -85.10000M | -192.60000M | -92.10000M | -62.40000M |
| Change to account receivables | -28.98914M | -53.70000M | -13.70000M | -145.60000M | 23.60M |
| Sale purchase of stock | -18.19318M | -37.60000M | - | -157.20000M | -3.80000M |
| Other cashflows from financing activities | -1.49944M | - | 12.70M | -0.10000M | 18.20M |
| Change to netincome | - | - | - | -98.40000M | -1.40000M |
| Capital expenditures | 335.17M | 345.80M | 338.30M | 286.70M | 290.10M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -71.27330M | -51.00000M | -206.70000M | -155.90000M | -36.40000M |
| Stock based compensation | 26.50M | 23.40M | 19.70M | 13.00M | 12.40M |
| Other non cash items | 23.69M | -55.40000M | 50.70M | -3.60000M | 24.00M |
| Free cash flow | 452.83M | 321.50M | 107.10M | 188.40M | 521.00M |
Sector: Healthcare Industry: Diagnostics & Research
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BMXMF bioMérieux S.A |
- -% | 83.31 | 29.26 | 19.27 | 3.43 | 2.58 | 2.59 | 12.40 |
| TMO Thermo Fisher Scientific Inc |
8.08 1.70% | 482.03 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
8.56 4.81% | 186.64 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| A Agilent Technologies Inc |
0.97 0.71% | 138.37 | 34.36 | 26.39 | 6.59 | 7.14 | 6.78 | 23.56 |
| IDXX IDEXX Laboratories Inc |
4.01 0.72% | 564.74 | 49.99 | 45.66 | 11.29 | 27.85 | 11.46 | 34.46 |
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL, a rapid AST system; ETEST, a gradient method on culture media; BIOMERIEUX EPISEQ CS, a whole genome sequencing solution for epidemiologic monitoring; VIDAS, a specific marker of severe bacterial infections/sepsis; and Biomérieux vision suite, a software that provides information to support diagnosis and clinical decision making. It also provides culture media and associated instruments; ARGENE that provides PCR tests for diagnosing viral respiratory diseases; EMAG system and NUCLISENS extraction reagents for DNA and RNA extraction; GENE-UP and VERIFLOW for detection of microorganisms for the food industry; ETEST for manual measurement of minimum inhibitory concentration of an antibiotic; API and RAPIDEC CARBA NP for identification of bacteria and manual antimicrobial susceptibility testing; BIOBALL for quantitative microbiological quality control; CHEMUNEX, a microbiology instrument; ENDONEXT for detection of endotoxins; TEMPO for fluorescence counting of bacteria; and Hybiome, a CLIA technology, as well as lab consultancy service and training modules. The company was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. operates as a subsidiary of Institut Mérieux SA.
376 Chemin De l?Orme, Marcy-l'Étoile, France, 69280
| Name | Title | Year Born |
|---|---|---|
| Mr. Alexandre Merieux | Chairman & CEO | 1974 |
| Mr. Pierre Boulud | Chief Operating Officer of Clinical Operations | 1971 |
| Mr. Frederic Beseme | Head of CSR | 1956 |
| Mr. Guillaume Bouhours | Exec. VP of Purchasing and Information Systems & CFO | 1976 |
| Sylvain Morgeau | Investor Relations | NA |
| Ms. Valerie Leylde | Exec. VP of HR, Communications & CSR | NA |
| Mr. François Lacoste | Exec. VP of R&D | NA |
| Mr. Mark Miller | Exec. VP of Medical Affairs | NA |
| Mr. Pierre Charbonnier | Exec. VP of Quality, Manufacturing & Supply Chain | NA |
| Mr. Yasha Mitrotti | Exec. VP of Industrial Microbiology | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.